Abiopharma

🔍 Almstead Neil Gregory (Executive)

Company: PTC THERAPEUTICS, INC. (PTCT)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 17,500 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 118,382.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 520 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 6,956.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 43,750 shares of Stock Option (Right to Buy) at $76.74 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-01 | equity_swap_involved: 0 | shares_owned_after: 43,750.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Restricted stock units granted on January 2, 2026 that vest in four equal installments over four years, commencing on January 2, 2027.
• F2: Includes 257 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended December 31, 2025.
• F3: This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027.